NASDAQ:NVLN - Novelion Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.54 -0.11 (-3.01 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$3.65
Today's Range$3.50 - $3.74
52-Week Range$2.96 - $7.33
Volume17,700 shs
Average Volume58,264 shs
Market Capitalization$73.71 million
P/E Ratio-0.52
Dividend YieldN/A
Beta0.94
Novelion Therapeutics logoNovelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVLN
CUSIPN/A
Phone617-500-7867

Debt

Debt-to-Equity Ratio-6.52
Current Ratio1.33
Quick Ratio1.13

Price-To-Earnings

Trailing P/E Ratio-0.52
Forward P/E Ratio-0.57
P/E GrowthN/A

Sales & Book Value

Annual Sales$138.44 million
Price / Sales0.48
Cash FlowN/A
Price / CashN/A
Book Value$0.80 per share
Price / Book4.43

Profitability

EPS (Most Recent Fiscal Year)($6.81)
Net Income$-126,710,000.00
Net Margins-109.01%
Return on Equity-240.54%
Return on Assets-23.32%

Miscellaneous

Employees180
Outstanding Shares18,850,000
Market Cap$73.71 million

Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc (NASDAQ:NVLN) released its earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.64) earnings per share for the quarter. The biotechnology company earned $31.90 million during the quarter. Novelion Therapeutics had a negative net margin of 109.01% and a negative return on equity of 240.54%. View Novelion Therapeutics' Earnings History.

When is Novelion Therapeutics' next earnings date?

Novelion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Novelion Therapeutics.

What price target have analysts set for NVLN?

1 equities research analysts have issued 1 year target prices for Novelion Therapeutics' stock. Their predictions range from $5.00 to $5.00. On average, they expect Novelion Therapeutics' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 41.2% from the stock's current price. View Analyst Price Targets for Novelion Therapeutics.

What is the consensus analysts' recommendation for Novelion Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novelion Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novelion Therapeutics.

Who are some of Novelion Therapeutics' key competitors?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the folowing people:
  • Dr. Mark H. N. Corrigan, Exec. Chairman (Age 60)
  • Mr. Jeffrey S. Hackman, Interim CEO, Exec. VP & COO (Age 56)
  • Mr. Michael D. Price, Exec. VP & CFO (Age 60)
  • Dr. Murray Stewart M.D., Exec. VP and Head of R&D (Age 58)
  • Mr. Benjamin S. Harshbarger, Gen. Counsel & Corp. Sec. (Age 49)

Has Novelion Therapeutics been receiving favorable news coverage?

Headlines about NVLN stock have been trending somewhat positive on Saturday, according to Accern. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novelion Therapeutics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Novelion Therapeutics.

Who are Novelion Therapeutics' major shareholders?

Novelion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (9.51%), Healthcare Value Capital LLC (6.97%), Millennium Management LLC (1.75%), Prosight Management LP (1.03%), LMR Partners LLP (0.27%) and BlackRock Inc. (0.23%). Company insiders that own Novelion Therapeutics stock include Donald K Stern and Jason Aryeh. View Institutional Ownership Trends for Novelion Therapeutics.

Which institutional investors are selling Novelion Therapeutics stock?

NVLN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Stonepine Capital Management LLC, Schwab Charles Investment Management Inc. and Prosight Management LP. View Insider Buying and Selling for Novelion Therapeutics.

Which institutional investors are buying Novelion Therapeutics stock?

NVLN stock was bought by a variety of institutional investors in the last quarter, including Healthcare Value Capital LLC, Millennium Management LLC and LMR Partners LLP. Company insiders that have bought Novelion Therapeutics stock in the last two years include Donald K Stern and Jason Aryeh. View Insider Buying and Selling for Novelion Therapeutics.

How do I buy shares of Novelion Therapeutics?

Shares of NVLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of NVLN stock can currently be purchased for approximately $3.54.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $73.71 million and generates $138.44 million in revenue each year. The biotechnology company earns $-126,710,000.00 in net income (profit) each year or ($6.81) on an earnings per share basis. Novelion Therapeutics employs 180 workers across the globe.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company can be reached via phone at 617-500-7867 or via email at [email protected]


MarketBeat Community Rating for Novelion Therapeutics (NASDAQ NVLN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  297
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel